Petrovax began supplying quadrivalent influenza vaccine to the Russian market and abroad

Petrovax Pharm announced the start of supplies of the quadrivalent vaccine for influenza prevention, Grippol® Quadrivalent. The total supply of the vaccine for Russian and foreign markets in 2022 will amount to more than 2.5 million doses.

Grippol® Quadrivalent vaccine was registered in Russia in 2018, the product is manufactured in Russia with the use of technology of a full manufacturing cycle of the finished dosage form (FDF) in accordance with GMP standards at the company's own production complex. This influenza vaccine protects against 4 strains: 2 type A viruses (H1N1 and H3N2) and type B virus of 2 lines (B/Yamagata + B/Victoria). The azoximer bromide adjuvant, which is included in the composition of the vaccine, reduces the amount of antigens in the vaccine by three times and provides a pronounced humoral and cellular immune response, which is confirmed by scientific publications in the international peer-reviewed journals Frontiers in Immunology, Vaccine and others.[1],[2],[3],[4],[5],[6]

Grippol® Quadrivalent was developed according to the technology for the manufacture of the Grippol ® family vaccines, which are included in the state immunization programs in a number of countries, have a broad evidence base and have been used for many years. The creation and supply of the vaccine is in line with the implementation of the National Strategy for the Development of Immunoprophylaxis of Infectious Diseases for the period up to 2035, within the framework of which Russia approved a plan for the transition to the use of quadrivalent vaccines for influenza prevention for the period 2021-2025.
“Maintaining and strengthening the immunity of citizens is one of the key activities of the company. Supplies of the modern Grippol® Quadrivalent vaccine not only open up additional opportunities for protecting Russian patients from the influenza virus, but also expand the company's export potential,”,
— said Mikhail Grubman, Managing Director of Petrovax Pharm biotechnology business.

Since 2012, quadrivalent vaccines 8 have been recommended by WHO as being the most effective against influenza 9 . All influenza vaccines used for immunization in the United States in recent years, including those used in the pediatric segment, are quadrivalent. Most EU countries also use predominantly quadrivalent vaccines[10],[11],[12]

According to experts, vaccination should take place 2-3 weeks before the increase in the incidence of influenza, the most suitable period for vaccination is from September to November. During the COVID-19 pandemic, influenza vaccination is part of the prevention of seasonal respiratory viral infections and it reduces the risk of infection and severe illness.

Petrovax is the largest exporter of influenza vaccines 13 , the company has been supplying the trivalent Grippol® Plus vaccine to the Russian and foreign markets for over 14 years, and this year its supply will exceed 12.5 million doses.

1Vladimir Talayev, Irina Zaichenko, Maria Svetlova. Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity. Vaccine. 2020 Sep 29;38(42):6645-6655. doi: 10.1016/j.vaccine.2020.07.053. Epub 2020 Aug 29.

2Kostinov MP, Akhmatova NK, Khromova EA and Kostinova AM (2020) Cytokine Profile in Human Peripheral Blood Mononuclear Leukocytes Exposed to Immunoadjuvant and Adjuvant-Free Vaccines Against Influenza. Front. Immunol. 11:1351. doi: 10.3389/fimmu.2020.01351

3Kostinova AM, Akhmatova NK, Latysheva EA, Dagil YA, Klimova SV, Vlasenko AE, Khromova EA, Latysheva TV and Kostinov MP (2020) Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency. Front. Immunol. 11:1876. doi: 10.3389/fimmu.2020.01876"

4Kostinov, Mikhail ; Akhmatova, Nelli; Skhodova, Svetlana; Stolpnikova, Vera; Cherdantsev, Alexander; Vlasenko, Anna. (2018). The Impact of Adjuvanted and Non-Adjuvanted Influenza Vaccines on the Innate and Adaptive Immunity Effectors. 10.5772/intechopen.77006.

5Kostinov, M.P.; Latysheva, E.A.; Kostinova, A.M.; Akhmatova, N.K.; Latysheva, T.V.; Vlasenko, A.E.; Dagil, Y.A.; Khromova, E.A.; Polichshuk, V.B. Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency. Vaccines 2020, 8, 640.

6Kompier R, Neels P, Beyer W et al. Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine. [version 1; peer review: 1 approved]. F1000Research 2022, 11:259







1313 According to RNC Pharma, Pharmaceutical bulletin, 25 August 2020.

Previous news

Study results on the use of Polyoxidonium in severe COVID Patients